Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Reports Positive Phase 1 Results for GLPG1205

Published: Wednesday, December 04, 2013
Last Updated: Wednesday, December 04, 2013
Bookmark and Share
Company is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

Galapagos NV has announced that GLPG1205, a first-in-class molecule for inflammatory disorders, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. Galapagos is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.

The aim of the Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205. The randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium.

In the first part of the study, single ascending doses were evaluated. In the second part, the new compound was administered daily for 14 days.

GLPG1205 was safe and well-tolerated over a wide dose range in healthy volunteers. Engagement of the thus far undisclosed novel target was confirmed using a relevant biomarker.

GLPG1205 displayed a favorable pharmacokinetic and pharmacodynamic profile, potentially supporting once-daily dosing. The data shown in Phase 1 encourage Galapagos to progress GLPG1205 into a Phase 2A study in Inflammatory Bowel Disease (IBD).

"GLPG1205 is the first molecule against this target ever to be evaluated clinically, and we are pleased with the outcome of the Phase 1 study," said Piet Wigerinck, CSO of Galapagos. "Galapagos continues to deliver novel therapeutics from its unique target and drug discovery engine. GLPG1205 will be the fourth compound to enter Phase 2A in our portfolio of proprietary and partnered programs based on novel targets."

In 2007, Galapagos announced an alliance agreement with Janssen Pharmaceutica NV providing the option to worldwide, commercial licenses to certain Galapagos internal inflammatory disease programs.

These programs include a novel target for inflammatory disorders that was identified and validated by Galapagos using its proprietary target discovery engine.

Subsequent Galapagos research led to the discovery of GLPG1205, a first-in-class molecule that entered the clinic for inflammatory disorders. Galapagos is responsible for execution of Phase 1 and Phase 2A studies with GLPG1205.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Presents Favorable Phase 1 Data for IBD Target
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.
Tuesday, October 21, 2014
Galapagos Selects Pre-Clinical Candidate for Cystic Fibrosis
Start of Phase 1 expected before end 2014.
Tuesday, December 17, 2013
Galapagos Appoints David Smith as CEO of Service Division
David Smith was CFO of Galapagos for two years.
Wednesday, August 21, 2013
Galapagos Starts Phase Ib Clinical Study in Cancer Patients
Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients.
Tuesday, March 15, 2011
Galapagos Candidate Cachexia Drug, GLPG0492, Shows Good Safety and Profile Suitable for Once-Daily Oral Dosing
Company plans to initiate extended dose and Proof of Concept studies in 2011.
Friday, December 03, 2010
Galapagos Starts Phase II Clinical Trial in Rheumatoid Arthritis Patients
Galapagos NV announced that it has started a Phase II clinical study for the Company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA).
Tuesday, October 19, 2010
Galapagos' Affiliate BioFocus Extends Collaboration with Chiesi
BioFocus to provide medicinal chemistry and biology services, with an additional option for ADME services, for a Chiesi therapeutic program.
Thursday, October 14, 2010
Galapagos Initiates Phase I Study for JAK inhibitor GLPG0634
Company announces the acquisition of full rights to the compound from GSK.
Monday, August 09, 2010
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
Friday, July 16, 2010
Galapagos Completes Phase I Clinical Trials for Rheumatoid Arthritis Candidate Drug GLPG0259
Phase II efficacy study in rheumatoid arthritis patients planned to start later this year.
Wednesday, February 24, 2010
Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million
Galapagos will now start scale-up chemistry and safety evaluation to initiate Phase I clinical trials early 2011.
Tuesday, February 23, 2010
Galapagos Acquires Argenta Discovery's Service Operations
Newly acquired, worth €16.5 million, Argenta unit will operate in parallel to BioFocus.
Friday, February 05, 2010
Galapagos Initiates Nanocort® Phase II Clinical Trial for Multiple Sclerosis
A single administration of Nanocort will be compared to the standard steroid treatment of three methylprednisolone infusions to evaluate Nanocort in treating MS.
Tuesday, November 24, 2009
Galapagos Initiates Second Phase I Clinical Trial for GLPG0259
The new trial is based on the positive outcome of the first-in-human trial conducted earlier in 2009.
Thursday, September 10, 2009
Galapagos Successfully Completes First Phase I Study for GLPG0259
Clinical results demonstrate safety in man Pharmacokinetic profile supports once-daily oral dosing.
Thursday, August 06, 2009
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!